Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Nightingale secured a 0.7 MEUR agreement for the Italian Moli-sani study

By Frans-Mikael RostedtAnalyst
Nightingale Health

Translation: Original published in Finnish on 07/07/2025 at 09:03 am EEST

Nightingale was selected as the metabolomics analysis provider for the renowned Moli-sani study in Italy. The total value of the agreement is approximately EUR 728, and the service is planned to be implemented already by the end of 2025. The agreement is significant for the company's research business and supports our growth forecasts for the second half of 2025. The company's revenue from other European countries (including Italy) was some 0.8 MEUR in 2024, making the agreement a significant size in comparison. This is a project-based revenue item, but we believe the agreement is a good additional reference for Nightingale's technology.

The Moli-sani study, led by INM Neuromed, investigates risk factors associated with major chronic diseases. With Nightingale Health’s advanced technology, the study will now examine the impact of nutritional and environmental factors on health.   The study also explores biological signatures associated with healthy aging and aims to identify population subgroups with different responses to preventative interventions. Nightingale was selected for the project in accordance with Italian public procurement law, and the parties are now proceeding to finalize the service agreement.

Login required

This content is only available for logged in users

Create account

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures11.06.2025

202425e26e
Revenue4.45.28.2
growth-%4.2 %19.5 %57.5 %
EBIT (adj.)-18.6-17.3-16.2
EBIT-% (adj.)-426.6 %-331.4 %-197.6 %
EPS (adj.)-0.29-0.27-0.25
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Inderes Sisäpiiritieto: Merkittävä edistysaskel Yhdysvalloissa - Nightingale Healthin... Nightingale Health Oyj | Sisäpiiritieto | 09.02.2026...
4 hours ago
by Critter
24
Off to a great start, down about 15% from entry in three weeks.
2/6/2026, 9:49 AM
by TomPettynyt
2
Yeah, with that kind of selling pressure, many will soon take a massive hit on this.
2/6/2026, 9:45 AM
by PeterPan
0
The reason is that the market price set by shareholders for the company is still one hundred million euros, for a company whose revenue is six...
2/6/2026, 9:01 AM
by Pertti
7
It seems to have come down 40% in three months, without any real reason. In stocks like these, the decline tends to feed itself, so the trend...
2/6/2026, 8:55 AM
by Puutaheinää
1
There’s quite little buying interest in the air. There’s a risk that it will drift back toward the net cash level again, meaning prices well...
2/6/2026, 8:45 AM
by PeterPan
0
In a week, there will be a Sitra event to launch a project that has been under preparation for a year: The future of health data in the age ...
2/3/2026, 3:23 PM
by Puutaheinää
22
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.